Development of Drug Resistance in a Murine Mammary Tumor
Author Information
Author(s): T.J. McMillan, T.C. Stephens, G.G. Steel
Primary Institution: Radiotherapy Research Unit, Institute of Cancer Research, Sutton, Surrey, UK.
Hypothesis
The study aims to examine the validity of existing models of drug-resistance development in a transplantable murine mammary tumor.
Conclusion
The study found that existing models of drug-resistance development do not adequately explain the results obtained.
Supporting Evidence
- Repeated high dose drug treatment reduced tumor response as measured by growth delay and clonogenic cell survival.
- The growth delay produced by 12mg kg-1 melphalan dropped from 8.6 days to 2.1 days after 16 treatments.
- Clonogenic survival assays showed significant differences between wild-type and drug-resistant lines.
- Cross-resistance patterns were observed between different drugs used in the study.
Takeaway
The study looked at how some cancer cells become resistant to drugs over time, showing that this resistance doesn't always happen the way scientists thought it would.
Methodology
The study involved treating murine mammary carcinoma with melphalan, cyclophosphamide, and cis-platinum, assessing growth delay and clonogenic cell survival.
Limitations
The study's findings may not fully apply to human tumors due to differences in tumor biology.
Participant Demographics
Male WHT mice aged 8-10 weeks, weighing 28-34g.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Want to read the original?
Access the complete publication on the publisher's website